Cited by 1,110Liver Disease Diagnosis and TreatmentInflammasome and immune disordersLiver physiology and pathology

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

Open access

Mridha, Auvro R., Wree, Alexander, Robertson, Avril A.B., Yeh, Matthew M., Johnson, Casey D., Van Rooyen, Derrick M., Haczeyni, Fahrettin, Teoh, Narci C.-H., Savard, Christopher, Ioannou, George N., Masters, Seth L., Schroder, Kate, Cooper, Matthew A., Feldstein, Ariel E., Farrell, Geoffrey C.·2017·Journal of Hepatology

DOI 10.1016/j.jhep.2017.01.022PMC PMC6536116

Open this paper in CoChat — free account

Abstract

Background & aims NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis.Methods We fed foz/foz and wild-type mice an atherogenic diet for 16weeks, gavaged MCC950 or vehicle until 24weeks, then determined NAFLD phenotype. In mice fed an methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle for 6weeks and determined the effects on liver fibrosis.Results In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1β, active caspase-1 and IL-1β increased at 24weeks, in association with cholesterol crystal formation and NASH pathology; plasma IL-1β, IL-6, MCP-1, ALT/AST all increased. MCC950 treatment normalized hepatic caspase 1 and IL-1β expression, plasma IL-1β, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathology, and liver fibrosis. In vitro, cholesterol crystals activated Kupffer cells and macrophages to release IL-1β; MCC950 abolished this, and the associated neutrophil migration. MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in hepatic caspase 1 and IL-1β, lowered numbers of macrophages and neutrophils in the liver, and improved liver fibrosis.Conclusion MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and fibrosis in obese diabetic mice. This is potentially attributable to the blockade of cholesterol crystal-mediated NLRP3 activation in myeloid cells. MCC950 reduced liver fibrosis in MCD-fed mice. Targeting NLRP3 is a logical direction in pharmacotherapy of NASH.Lay summary Fatty liver disease caused by being overweight with diabetes and a high risk of heart attack, termed non-alcoholic steatohepatitis (NASH), is the most common serious liver disease with no current treatment. There could be several causes of inflammation in NASH, but activation of a protein scaffold within cells termed the inflammasome (NLRP3) has been suggested to play a role. Here we show that cholesterol crystals could be one pathway to activate the inflammasome in NASH. We used a drug called MCC950, which has already been shown to block NLRP3 activation, in an attempt to reduce liver injury in NASH. This drug partly reversed liver inflammation, particularly in obese diabetic mice that most closely resembles the human context of NASH. In addition, such dampening of liver inflammation in NASH achieved with MCC950 partly reversed liver scarring, the process that links NASH to the development of cirrhosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2017.01.022

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Inflammasomes
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Self-citation
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Self-citation
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites†
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation
Rajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039
NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice
Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Hepatology · doi:10.1002/hep.26592 · Cited by 945
Self-citation
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
Cusi, K. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 940

Flagged first, then by citations

Show all 49 references

Sorted by citations

Items 101–200 of 999

Berberine Inhibits Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome Activation and Pyroptosis in Nonalcoholic Steatohepatitis via the ROS/TXNIP Axis
Mai, W., Xu, Y., Xu, J., Zhao, D., Ye, L., Yu, G., Wang, Z., Lu, Q., Lin, J., Yang, T., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00185 · Cited by 129
Role of miR-223 in the pathophysiology of liver diseases
Ye, D., Zhang, T., Lou, G., & Liu, Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0153-7 · Cited by 125
Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation
Wang, Y., Chen, C., Chen, J., Sang, T., Peng, H., Lin, X., Zhao, Q., Chen, S., Eling, T. E., & Wang, X. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102322 · Cited by 130
Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice
Ren, P., Wu, D., Appel, R., Zhang, L., Zhang, C., Luo, W., Robertson, A. A. B., Cooper, M. A., Coselli, J. S., Milewicz, D. M., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014044 · Cited by 128
Self-citation
NOD-Like Receptor Protein 3 Inflammasome-Dependent IL-1β Accelerated ConA-Induced Hepatitis
Luan, J., Zhang, X., Wang, S., Li, Y., Fan, J., Chen, W., Zai, W., Wang, S., Wang, Y., Chen, M., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00758 · Cited by 123
Pathway network of pyroptosis and its potential inhibitors in acute kidney injury
Li, N., Wang, Y., Wang, X., Sun, N., & Gong, Y.-H. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106033 · Cited by 129
The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment
Yu, L., Hong, W., Lu, S., Li, Y., Guan, Y., Weng, X., & Feng, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.780496 · Cited by 126
MASH: the nexus of metabolism, inflammation, and fibrosis
Steinberg, G. R., Carpentier, A. C., & Wang, D. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186420 · Cited by 135
A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation
Zhang, C., Zhu, X., Li, L., Ma, T., Shi, M., Yang, Y., & Fan, Q. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s199802 · Cited by 119
Mesenchymal Stem Cell-Derived Extracellular Vesicles in Liver Immunity and Therapy
Wu, R., Fan, X., Wang, Y., Shen, M., Zheng, Y., Zhao, S., & Yang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.833878 · Cited by 125
NLRP3 inflammasome inhibition attenuates cisplatin-induced renal fibrosis by decreasing oxidative stress and inflammation
Li, S., Lin, Q., Shao, X., Mou, S., Gu, L., Wang, X., Zhang, Z., Shen, J., Zhou, Y., Qi, C., et al. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.07.001 · Cited by 116
Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling
Torre, S. D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.572490 · Cited by 125
Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis
Li, H., Zhou, Y., Wang, H., Zhang, M., Qiu, P., Zhang, M., Zhang, R., Zhao, Q., & Liu, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01169 · Cited by 117
Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction
Li, Q., Feng, H., Wang, H., Wang, Y., Mou, W., Xu, G., Zhang, P., Li, R., Shi, W., Wang, Z., et al. (2021) · EMBO Reports · doi:10.15252/embr.202153499 · Cited by 111
XBP1-mediated activation of the STING signalling pathway in macrophages contributes to liver fibrosis progression
Wang, Q., Bu, Q., Liu, M., Zhang, R., Gu, J. P., Li, L., Zhou, J., Liang, Y., Su, W., Liu, Z., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100555 · Cited by 117
Geniposide suppresses NLRP3 inflammasome-mediated pyroptosis via the AMPK signaling pathway to mitigate myocardial ischemia/reperfusion injury
Li, H., Yang, D., Zhang, Y., Zheng, F., Gao, F., Sun, J., & Shi, G. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00616-5 · Cited by 110
Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe?
Chen, J., Deng, X., Liu, Y., Tan, Q., Huang, G., Che, Q., Guo, J., & Su, Z. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.47143 · Cited by 118
Human Autoinflammatory Diseases Mediated by NLRP3-, Pyrin-, NLRP1-, and NLRC4-Inflammasome Dysregulation Updates on Diagnosis, Treatment, and the Respective Roles of IL-1 and IL-18
Alehashemi, S., & Goldbach‐Mansky, R. T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01840 · Cited by 108
Bax inhibitor‐1 protects from nonalcoholic steatohepatitis by limiting inositol‐requiring enzyme 1 alpha signaling in mice
Lebeaupin, C., Vallée, D., Rousseau, D., Patouraux, S., Bonnafous, S., Adam, G., Luciano, F., Luci, C., Anty, R., Iannelli, A., et al. (2018) · Hepatology · doi:10.1002/hep.29847 · Cited by 111
Apigenin ameliorates HFD-induced NAFLD through regulation of the XO/NLRP3 pathways
Lv, Y., Gao, X., Luo, Y., Fan, W., Shen, T., Ding, C., Yao, M., Song, S., & Yan, L. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.05.015 · Cited by 108
Inflammasome activation in acute lung injury
McVey, M. J., Steinberg, B. E., & Goldenberg, N. M. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00303.2020 · Cited by 108
Reduction of high-fat diet-induced liver proinflammatory state by eicosapentaenoic acid plus hydroxytyrosol supplementation: involvement of resolvins RvE1/2 and RvD1/2
Echeverría, F., Valenzuela, R., Espinosa, A., Bustamante, A., Álvarez, D., Gonzalez‐Mañán, D., Ortíz, M., Soto-Alarcón, S. A., & Videla, L. A. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.09.012 · Cited by 108
Role of Oxidative Stress in Liver Disorders
Conde de la Rosa, L., Goicoechea, L., Torres, S., Garcia-Ruiz, C., & Fernandez-Checa, J. C. (2022) · Livers · doi:10.3390/livers2040023 · Cited by 107
SLC7A11-ROS/αKG-AMPK axis regulates liver inflammation through mitophagy and impairs liver fibrosis and NASH progression
Lv, T., Fan, X., He, C., Zhu, S., Xiong, X., Yan, W., Liu, M., Xu, H., Shi, R., & He, Q. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103159 · Cited by 114
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC
Xia, Y., Wang, Y., Xiong, Q., He, J., Wang, H., Islam, M., Zhou, X., Kim, A. C., Zhang, H., Huang, H., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000762 · Cited by 116
Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation
Yan, T., Wang, H., Cao, L.-J., Wang, Q., Takahashi, S., Yagai, T., Li, G.-L., Krausz, K., Wang, G.-J., Gonzalez, F., et al. (2018) · Drug Metabolism And Disposition · doi:10.1124/dmd.118.082008 · Cited by 98
Aflatoxin B1 enhances pyroptosis of hepatocytes and activation of Kupffer cells to promote liver inflammatory injury via dephosphorylation of cyclooxygenase-2: an in vitro, ex vivo and in vivo study
Zhang, L., Zhan, D.-L., Chen, Y., Wang, W., He, C., Lin, Y., Lin, Z., & Lin, Z. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02572-w · Cited by 108
Regulating metabolic inflammation by nutritional modulation
Charles‐Messance, H., Mitchelson, K. A. J., Castro, E. D. M., Sheedy, F. J., & Roche, H. M. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.08.013 · Cited by 121
RIP1 kinase activity promotes steatohepatitis through mediating cell death and inflammation in macrophages
Tao, L., Yi, Y., Chen, Y., Zhang, H., Jie, J., Zhang, W., Xu, Q., Li, Y., Ørning, P., Lien, E., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-00668-w · Cited by 105
Disulfiram suppresses NLRP3 inflammasome activation to treat peritoneal and gouty inflammation
Deng, W., Yang, Z., Hu, Y., Ou, Y., Hu, W., & Sun, P. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.03.007 · Cited by 106
The Inflammasome in Times of COVID-19
Vaccari, J. C. D. R., Dietrich, W. D., Keane, R. W., & Vaccari, J. P. D. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583373 · Cited by 104
Chicoric Acid Ameliorates Nonalcoholic Fatty Liver Disease via the AMPK/Nrf2/NFκB Signaling Pathway and Restores Gut Microbiota in High-Fat-Diet-Fed Mice
Ding, X., Jian, T., Li, J., Lv, H., Tong, B., Li, J., Meng, X., Ren, B., & Chen, J. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9734560 · Cited by 103
Macrophage Sphingosine 1-Phosphate Receptor 2 Blockade Attenuates Liver Inflammation and Fibrogenesis Triggered by NLRP3 Inflammasome
Hou, L., Yang, L., Chang, N., Zhao, X., Zhou, X., Dong, C., Liu, F., Yang, L., & Li, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01149 · Cited by 102
Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases
Cai, J., Xu, M. M., Zhang, X., & Li, H. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013003 · Cited by 101
Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease
Katsarou, A., Moustakas, I. I., Pyrina, I., Lembessis, P., Koutsilieris, M., & Chatzigeorgiou, A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i17.1993 · Cited by 103
Cryptotanshinone specifically suppresses NLRP3 inflammasome activation and protects against inflammasome-mediated diseases
Liu, H., Zhan, X., Xu, G., Wang, Z., Li, R., Wang, Y., Qin, Q., Shi, W., Hou, X., Yang, R., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105384 · Cited by 101
The NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis
Knorr, J., Wree, A., Tacke, F., & Feldstein, A. E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708540 · Cited by 99
Self-citation
Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies
Lee, Y. A., & Friedman, S. L. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13380 · Cited by 104
Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases
Zhao, P., & Saltiel, A. R. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.011356 · Cited by 106
Inflammasome: A Double-Edged Sword in Liver Diseases
Luan, J., & Ju, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02201 · Cited by 96
Interleukin-1 in obesity-related low-grade inflammation: From molecular mechanisms to therapeutic strategies
Ghanbari, M., Maragheh, S. M., Aghazadeh, A., Mehrjuyan, S. R., Hussen, B. M., Shadbad, M. A., Dastmalchi, N., & Safaralizadeh, R. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107765 · Cited by 101
NLRP3 Inflammasome Activation: A Therapeutic Target for Cerebral Ischemia–Reperfusion Injury
Wang, L., Ren, W., Wu, Q., Liu, T., Wei, Y. L., Ding, J., Zhou, C., Xu, H., & Yang, S. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.847440 · Cited by 105
The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice
Qu, J., Yuan, Z., Wang, G., Wang, X., & Li, K. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.02.016 · Cited by 96
Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease
Porras, D., Nistal, E., Martínez‐Flórez, S., González‐Gallego, J., García‐Mediavilla, M. V., & Sánchez‐Campos, S. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01813 · Cited by 97
The Inflammasome in Chronic Complications of Diabetes and Related Metabolic Disorders
Menini, S., Iacobini, C., Vitale, M., & Pugliese, G. (2020) · Cells · doi:10.3390/cells9081812 · Cited by 97
Autophagy: Dual Response in the Development of Hepatocellular Carcinoma
Yazdani, H. O., Huang, H., & Tsung, A. (2019) · Cells · doi:10.3390/cells8020091 · Cited by 94
Bidirectional Role of NLRP3 During Acute and Chronic Cholestatic Liver Injury
Frissen, M., Liao, L., Schneider, K. M., Djudjaj, S., Haybaeck, J., Wree, A., Rolle-Kampczyk, U. E., von Bergen�, M., Latz, E., Boor, P., et al. (2020) · Hepatology · doi:10.1002/hep.31494 · Cited by 93
Self-citation
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis
Knorr, J., Kaufmann, B. K., Inzaugarat, M. E., Holtmann, T. M., Geisler, L. J., Hundertmark, J., Kohlhepp, M. S., Boosheri, L. M., Chilin-Fuentes, D., Birmingham, A., et al. (2022) · Hepatology · doi:10.1002/hep.32776 · Cited by 99
Self-citation
Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
Kuchay, M. S., Choudhary, N. S., & Ramos‐Molina, B. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00951.2024 · Cited by 104
A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage
Huang, S., Wu, Y., Zhao, Z., Wu, B., Sun, K., Wang, H., Li, Q., Bai, F., Leng, Y., & Tang, W. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154797 · Cited by 96
Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis
Sharma, S. K., Guillou, D. L., & Chen, J. Y. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00832-w · Cited by 100
STING contributes to lipopolysaccharide-induced tubular cell inflammation and pyroptosis by activating endoplasmic reticulum stress in acute kidney injury
Cao, Y., Chen, X., Zhu, Z., Luo, Z., Hao, Y., Yang, X., Feng, J., Zhang, Z., Hu, J., Jian, Y., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06600-1 · Cited by 102
Oxidized linoleic acid metabolites induce liver mitochondrial dysfunction, apoptosis, and NLRP3 activation in mice
Schuster, S., Johnson, C. D., Hennebelle, M., Holtmann, T. M., Taha, A. Y., Kirpich, I., Eguchi, A., Ramsden, C. E., Papouchado, B. G., McClain, C. J., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m083741 · Cited by 91
Self-citation
Mulberrin confers protection against hepatic fibrosis by Trim31/Nrf2 signaling
Ge, C., Tan, J., Lou, D., Zhu, L., Zhong, Z., Dai, X., Sun, Y., Kuang, Q., Zhao, J., Wang, L., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102274 · Cited by 90
Propionate and butyrate attenuate macrophage pyroptosis and osteoclastogenesis induced by CoCrMo alloy particles
Wu, Y., Zhang, C., Teng, Y., Pan, Y., Liu, N., Liu, P.-X., Zhu, X. H., Su, X., & Lin, J. (2022) · Military Medical Research · doi:10.1186/s40779-022-00404-0 · Cited by 91
Inflammasomes and Pyroptosis of Liver Cells in Liver Fibrosis
Gan, C., Cai, Q., Tang, C., & Gao, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896473 · Cited by 94
Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor
McBride, C., Trzoss, L., Povero, D., Lazić, M., Ambrus-Aikelin, G., Santini, A. M., Pranadinata, R. F., Bain, G., Stansfield, R. K., Stafford, J. A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01250 · Cited by 95
Molecular mechanisms and regulation of inflammasome activation and signaling: sensing of pathogens and damage molecular patterns
Dubey, S. R., Turnbull, C., Pandey, A., Zhao, A., Kurera, M., Al-Zidan, R. N., Shen, C. X., Gautam, M., Mahajan, S., Jadhav, P. S., et al. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01354-y · Cited by 101
Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy
Li, X., Shao, M., Zeng, X., Qian, P., & Huang, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00764-4 · Cited by 94
Pharmacological targeting of NLRP3 deubiquitination for treatment of NLRP3-associated inflammatory diseases
Ren, G., Li, J., Zhang, X., Wang, Y., Xiao, Y., Zhang, X., Liu, X., Zhang, W., Ma, W., Zhang, J., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abe2933 · Cited by 88
Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis
Zhou, J., Tripathi, M., Ho, J. P., Widjaja, A. A., Shekeran, S. G., Camat, M. D., James, A., Wu, Y., Ching, J., Kovalik, J., et al. (2022) · Thyroid · doi:10.1089/thy.2021.0621 · Cited by 86
MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes
Bakhshi, S., & Shamsi, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108595 · Cited by 85
RIP Kinases in Liver Cell Death, Inflammation and Cancer
Kondylis, V., & Pasparakis, M. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.10.007 · Cited by 85
NLRP3 inflammasome activation from Kupffer cells is involved in liver fibrosis of Schistosoma japonicum-infected mice via NF-κB
Zhang, W., Fang, Z., & Liu, W. (2019) · Parasites & Vectors · doi:10.1186/s13071-018-3223-8 · Cited by 86
Innate immune regulatory networks in hepatic lipid metabolism
Bai, L., & Li, H. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01765-1 · Cited by 86
Circadian Control of Inflammasome Pathways: Implications for Circadian Medicine
Pourcet, B., & Duez, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01630 · Cited by 88
Pyroptosis in diabetic nephropathy
Mamun, A. A., Mimi, A. A., Wu, Y., Zaeem, M., Aziz, M. A., Suchi, S. A., Alyafeai, E., Munir, F., & Xiao, J. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.09.003 · Cited by 87
Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD
Pierantonelli, I., Rychlicki, C., Agostinelli, L., Giordano, D. M., Gaggini, M., Fraumene, C., Saponaro, C., Manghina, V., Sartini, L., Mingarelli, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11744-6 · Cited by 82
Crystalline silica-induced macrophage pyroptosis interacting with mitophagy contributes to pulmonary fibrosis via modulating mitochondria homeostasis
Wei, Y., You, Y., Zhang, J., Ban, J., Min, H., Li, C. R., & Chen, J. (2023) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2023.131562 · Cited by 83
Inhibition of the NOD-Like Receptor Protein 3 Inflammasome Is Protective in Juvenile Influenza A Virus Infection
Coates, B. M., Staricha, K. L., Ravindran, N., Koch, C. M., Cheng, Y., Davis, J. M., Shumaker, D. K., & Ridge, K. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00782 · Cited by 81
Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease
Yan, Y., Liu, C., Zhao, S., Wang, X., Wang, J., Zhang, H., Wang, Y., & Zhao, G. (2020) · AMB Express · doi:10.1186/s13568-020-01038-y · Cited by 81
Nuclear Receptors in the Control of the NLRP3 Inflammasome Pathway
Duez, H., & Pourcet, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.630536 · Cited by 85
Hepatic Stellate Cell-Immune Interactions in NASH
Carter, J. K., & Friedman, S. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.867940 · Cited by 79
Cannabidiol protects livers against nonalcoholic steatohepatitis induced by high‐fat high cholesterol diet via regulating NF‐κB and NLRP3 inflammasome pathway
Huang, Y., Wan, T., Pang, N., Zhou, Y., Jiang, X., Li, B., Gu, Y., Huang, Y., Ye, X., Lian, H., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28728 · Cited by 79
Alpinetin exerts anti-inflammatory, anti-oxidative and anti-angiogenic effects through activating the Nrf2 pathway and inhibiting NLRP3 pathway in carbon tetrachloride-induced liver fibrosis
Zhu, Z., Hu, R., Li, J., Xing, X., Chen, J., Zhou, Q. X., & Sun, J. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107660 · Cited by 80
Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
Kim, K. H., & Lee, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00485 · Cited by 77
ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model
Gaul, S., Geisler, L. J., McGeough, M. D., Johnson, C. D., Zagórska, A., Li, L., Wree, A., Barry, V., Mikaelian, I., Jih, L., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.123294 · Cited by 77
Self-citation
Carnosol inhibits inflammasome activation by directly targeting HSP90 to treat inflammasome-mediated diseases
Shi, W., Xu, G., Zhan, X., Gao, Y., Wang, Z., Fu, S., Qin, N., Hou, X., Ai, Y., Wang, C., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2460-x · Cited by 76
DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates
Qu, P., Rom, O., Li, K., Jia, L., Gao, X., Liu, Z., Ding, S., Zhao, M., Wang, H., Chen, S., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.03.013 · Cited by 80
Hepatic danger signaling triggers TREM2 + macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation
Zhou, L., Qiu, X., Meng, Z., Liu, T., Chen, Z., Zhang, P., Kuang, H., Pan, T., Lu, Y., Qi, L., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk1866 · Cited by 85
Autophagy inhibition attenuates the induction of anti-inflammatory effect of catalpol in liver fibrosis
Liu, Z., Zhu, P., Zhang, L., Xiong, B., Tao, J., Guan, W., Li, C., Chen, G., Gu, J., Duanmu, J., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.156 · Cited by 74
Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance
Roohani, S., & Tacke, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147249 · Cited by 79
The Role of Autophagy and NLRP3 Inflammasome in Liver Fibrosis
Tao, Y., Wang, N., Qiu, T., & Sun, X. (2020) · BioMed Research International · doi:10.1155/2020/7269150 · Cited by 74
The gut microbiota–bile acid axis: A potential therapeutic target for liver fibrosis
Zhang, Y., Li, Z.-J., Gou, H.-Z., Song, X., & Zhang, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.945368 · Cited by 77
Lycium barbarum polysaccharides improve hepatic injury through NFkappa-B and NLRP3/6 pathways in a methionine choline deficient diet steatohepatitis mouse model
Xiao, J., Wang, F., Liong, E. C., So, K., & Tipoe, G. L. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.09.151 · Cited by 73
Inhibition of NLRP3 Inflammasome Ameliorates Cerebral Ischemia-Reperfusion Injury in Diabetic Mice
Hong, P., Li, F., Gu, R., Fang, Y., Lai, L., Wang, Y., Tao, T., Xu, S., You, Z.-J., & Zhang, H. (2018) · Neural Plasticity · doi:10.1155/2018/9163521 · Cited by 74
The selective Nlrp3 inflammasome inhibitor Mcc950 attenuates lung ischemia-reperfusion injury
Xu, K., Wu, C., Tong, S., Peng, X., & Wang, S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.08.089 · Cited by 75
Exercise Intervention Mitigates Pathological Liver Changes in NAFLD Zebrafish by Activating SIRT1/AMPK/NRF2 Signaling
Zou, Y., Chen, Z., Sun, C., Yang, D. K., Zhou, Z., Peng, X., Zheng, L., & Tang, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010940 · Cited by 76
Gut–Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome
Pezzino, S., Sofia, M., Faletra, G., Mazzone, C., Litrico, G., Greca, G. L., & Latteri, S. (2022) · Biology · doi:10.3390/biology11111622 · Cited by 77
A TNFα/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates non-alcoholic steatohepatitis
Jin, K., Shi, Y., Zhang, H., Zhangyuan, G., Wang, F., Li, S., Chen, C., Zhang, J., Wang, H., Zhang, W., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.039 · Cited by 77
Hepatic Macrophage as a Key Player in Fatty Liver Disease
Xu, L., Liu, W., Bai, F., Xu, Y., Liang, X., Ma, C., & Gao, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708978 · Cited by 73
The strategies of targeting the NLRP3 inflammasome to treat inflammatory diseases
Jiang, H., Gong, T., & Zhou, R. (2019) · Advances in immunology · doi:10.1016/bs.ai.2019.11.003 · Cited by 71
PFOS facilitates liver inflammation and steatosis: An involvement of NLRP3 inflammasome‐mediated hepatocyte pyroptosis
Qin, Y., Gu, T., Ling, J., Luo, J., Zhao, J., Hu, B., Hua, L., Wan, C., & Jiang, S. (2021) · Journal of Applied Toxicology · doi:10.1002/jat.4258 · Cited by 71
Loss of MLKL ameliorates liver fibrosis by inhibiting hepatocyte necroptosis and hepatic stellate cell activation
Guo, R., Jia, X., Ding, Z., Wang, G., Jiang, M., Li, B., Chen, S., Xia, B., Zhang, Q., Liu, J., et al. (2022) · Theranostics · doi:10.7150/thno.71400 · Cited by 69
Role of hepatic stellate cell (HSC)-derived cytokines in hepatic inflammation and immunity
Gupta, G., Khadem, F., & Uzonna, J. E. (2018) · Cytokine · doi:10.1016/j.cyto.2018.09.004 · Cited by 72
The gut–liver axis in immune remodeling of hepatic cirrhosis
Guan, H., Zhang, X., Kuang, M., & Yu, J. Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.946628 · Cited by 73
Oxidative Stress and Redox Signaling in the Pathophysiology of Liver Diseases
Mooli, R. G. R., Mukhi, D., & Ramakrishnan, S. K. (2022) · Comprehensive physiology · doi:10.1002/cphy.c200021 · Cited by 134
Low-Dose Radiation Therapy Promotes Radiation Pneumonitis by Activating NLRP3 Inflammasome
Li, X., Gong, Y., Li, D., Li, X., Ou, Y., Jiang, L., Shu, P., Liu, X., Guo, F., Qin, D., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.02.643 · Cited by 68
Pyroptosis: Mechanisms and Links with Fibrosis
Song, Z., Gong, Q., & Guo, J. (2021) · Cells · doi:10.3390/cells10123509 · Cited by 68

Authors: Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., Masters, S. L., Schroder, K., Cooper, M. A., Feldstein, A. E., & Farrell, G. C.
Affiliations: Australian National University (AU)
University of California San Diego (US)
The University of Queensland (AU)
University of Washington (US)
Walter and Eliza Hall Institute of Medical Research (AU)
Corresponding author: Farrell, Geoffrey C.
ORCID: Mridha, Auvro R.
Wree, Alexander
Robertson, Avril A.B.
Yeh, Matthew M.
Johnson, Casey D.
Haczeyni, Fahrettin
Savard, Christopher
Ioannou, George N.
Masters, Seth L.
Schroder, Kate
Cooper, Matthew A.
Feldstein, Ariel E.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2017-05
Volume: 66
Issue: 5
Pages: 1037-1046
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2017.01.022
PMC: PMC6536116
OpenAlex: W2585046292
Cited by: 1,110
References: 49
Citations by year: 2026: 117 · 2025: 147 · 2024: 126 · 2023: 150 · 2022: 160 · 2021: 143 · 2020: 121 · 2019: 61 · 2018: 70 · 2017: 14
FWCI: 57.20
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
ANU Open Research (Australian National University) (submittedVersion, cc-by-nc-nd)
RWTH Publications (RWTH Aachen) (submittedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (U01AA022489, R21AA023574)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK113592)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: NLRP3 inflammasome, MCC950, nonalcoholic steatohepatitis, liver fibrosis, liver inflammation, IL-1β, caspase-1, cholesterol crystals, Kupffer cells, macrophages, neutrophil migration, methionine-choline-deficient diet, atherogenic diet, myeloid cells
MeSH terms: NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Disease Models, Animal, Female, Furans, Hepatitis, Heterocyclic Compounds, 4 or More Rings, Indenes, Liver Cirrhosis, Experimental, Sulfonamides, Sulfones, NF-kappa B, Reactive Oxygen Species, Mice, Interleukin-1beta, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks